Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Talazoparib slowed disease progression compared to chemotherapy in EMBRACA study.
FDA also approves genetic test to identify eligible patients.
New treatment options are available for those with breast cancer that has metastasized.
Talazoparib may offer an additional option for women with BRCA gene mutations.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.